Paratus Sciences Revenue

About Paratus Sciences

Paratus Sciences is unlocking novel disease targets and accelerating drug discovery by leveraging the extraordinary adaptive biology of bats. Bats’ numerous evolutionary adaptations allow them to resist developing many diseases, and also endow them with remarkable physiological fitness and longevity. At Paratus, we are utilizing these unique biological advantages as a roadmap to potentially address a broad spectrum of significant challenges to human health. Our proprietary discovery platform, which fully integrates cell biology, genomics, and informatics, empowers us with massive data inputs through which we are able to compare the evolved patterns of disease resistance and health management in bats with patterns of disease development and progression in humans. Through this data-driven comparative analysis, we aim to rapidly identify and prioritize novel targets and develop innovative therapeutics that can mimic bats’ adaptations in order to address or prevent human disease. Our initial discovery pipeline focuses on immunology and inflammation, and cardiometabolism, with the potential to expand to additional therapeutic areas, including oncology and aging. We also have an ongoing research collaboration with the National Institute of Allergy and Infectious Disease to explore virology applications with our approach. Our top-tier investor syndicate, including Polaris Partners, ARCH Venture Partners, ClavystBio, EcoR1 Capital, Leaps by Bayer, and Alexandria Venture Investments, and the $100 million we’ve raised to date, demonstrate a strong belief in the potential of our approach to impact and improve human health.

View contact profiles from Paratus Sciences